List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 264 studies with search of: "Sunitinib"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Not yet recruiting Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Sunitinib;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Sunitinib
2 Active, not recruiting A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies
Condition: Neoplasms
Interventions: Drug: Sunitinib, Pemetrexed;   Drug: Sunitinib, Pemetrexed
3 Active, not recruiting Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor
Conditions: Platinum Refractory Epithelial Ovarian Cancer;   Primary Cancer of the Peritoneum;   Cancer of the Fallopian Tube
Interventions: Drug: Sunitinib;   Drug: SUNITINIB
4 Recruiting A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
Conditions: Anaplastic Astrocytoma;   Glioblastoma
Intervention: Drug: Sunitinib Malate
5 Recruiting Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)
Condition: Renal Cell Carcinoma
Interventions: Drug: Sunitinib;   Procedure: Nephrectomy
6 Recruiting SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme
Condition: Glioblastoma Multiforme
Intervention: Drug: Sunitinib
7 Active, not recruiting Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
Conditions: Liposarcoma;   Leiomyosarcoma;   Fibrosarcoma
Intervention: Drug: Sunitinib Malate
8 Not yet recruiting Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Drug: Sunitinib;   Drug: Bevacizumab
9 Recruiting Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy
Condition: Carcinoma Renal Cells
Intervention: Drug: Sunitinib
10 Recruiting Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer
Condition: Stomach Neoplasms
Interventions: Drug: capecitabine;   Drug: oxaliplatin;   Drug: sunitinib malate;   Drug: capecitabine;   Drug: cisplatin;   Drug: sunitinib malate
11 Active, not recruiting Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Sunitinib Malate Continuous Daily Dosing;   Drug: Sunitinib Malate Schedule 4/2
12 Recruiting Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
Conditions: Paraganglioma;   Pheochromocytoma
Intervention: Drug: Sunitinib
13 Recruiting Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
Conditions: Renal Cell Cancer;   Kidney Cancer
Intervention: Drug: Sunitinib Malate
14 Recruiting Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Conditions: CNS Cancer;   Meningioma;   Intracranial Hemangiopericytoma;   Hemangioblastoma;   Neurofibromatosis
Intervention: Drug: Sunitinib
15 Recruiting Randomized Phase II Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced RCC
Condition: Metastatic Renal Cell Carcinoma, Clear Cell Type
Interventions: Drug: Sunitinib 2/1 schedule;   Drug: Sunitinib 4/2 schedule
16 Recruiting Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer
Condition: Colorectal Neoplasms
Interventions: Drug: sunitinib + mFOLFOX6;   Drug: bevacizumab + mFOLFOX6
17 Completed A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together
Conditions: Breast Cancer;   Neoplasms
Intervention: Drug: SU011248; Capecitabine
18 Active, not recruiting Ph I SU011248 + Irinotecan in Treatment of Pts w MG
Condition: Glioblastoma
Intervention: Drug: SU011248 & Irinotecan
19 Recruiting A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Intervention: Drug: Sunitinib Malate (Sutent)
20 Active, not recruiting Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
Condition: Prostate Cancer
Interventions: Drug: LHRH Agonist;   Drug: Sunitinib Malate;   Procedure: Radical Prostatectomy

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services